604 related articles for article (PubMed ID: 16125469)
41. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
[TBL] [Abstract][Full Text] [Related]
42. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
Chatterjee SK; Qin H; Manna S; Tripathi PK
Anticancer Res; 1999; 19(4B):2869-73. PubMed ID: 10652566
[TBL] [Abstract][Full Text] [Related]
43. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
[TBL] [Abstract][Full Text] [Related]
44. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
O-Sullivan I; Kim TS; Chopra A; Cohen EP
Anticancer Res; 2006; 26(2A):873-84. PubMed ID: 16619482
[TBL] [Abstract][Full Text] [Related]
46. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
47. Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma.
Kimura Y; Mizuno H; Satake K; Tahara H; Tsukuda M
Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1181-5. PubMed ID: 14623747
[TBL] [Abstract][Full Text] [Related]
48. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
49. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
50. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
[TBL] [Abstract][Full Text] [Related]
51. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus.
Gutierrez-Ramos JC; Andreu JL; Revilla Y; Viñuela E; Martinez C
Nature; 1990 Jul; 346(6281):271-4. PubMed ID: 1973822
[TBL] [Abstract][Full Text] [Related]
52. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma.
Bergmann C; Strauss L; Zeidler R; Lang S; Whiteside TL
Cancer Res; 2007 Sep; 67(18):8865-73. PubMed ID: 17875728
[TBL] [Abstract][Full Text] [Related]
53. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
54. [IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma].
Liu S; Lin Y; Tang S; Yang H; Liang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2001 Jun; 19(3):191-3. PubMed ID: 12539412
[TBL] [Abstract][Full Text] [Related]
55. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.
Morris EC; Tsallios A; Bendle GM; Xue SA; Stauss HJ
Proc Natl Acad Sci U S A; 2005 May; 102(22):7934-9. PubMed ID: 15908507
[TBL] [Abstract][Full Text] [Related]
56. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
57. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
58. [Studies of mouse interleukin-2 gene therapy for head, and neck sequamous cell carcinoma using polycationic liposome-mediated transduction].
Yang H; Liu S; Liang C; Peng W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):9-11, 30. PubMed ID: 15600166
[TBL] [Abstract][Full Text] [Related]
59. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
60. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
